1. Home
  2. GRNQ vs VRAX Comparison

GRNQ vs VRAX Comparison

Compare GRNQ & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenpro Capital Corp.

GRNQ

Greenpro Capital Corp.

N/A

Current Price

$10.71

Market Cap

23.6M

Sector

Technology

ML Signal

N/A

VRAX

Virax Biolabs Group Limited

N/A

Current Price

$2.64

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRNQ
VRAX
Founded
2013
2013
Country
Malaysia
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.6M
2.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
GRNQ
VRAX
Price
$10.71
$2.64
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
123.2K
482.4K
Earning Date
05-13-2026
06-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,673,997.00
N/A
Revenue This Year
N/A
$217,274.83
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.55
N/A
52 Week Low
$1.04
$0.10
52 Week High
$22.70
$13.19

Technical Indicators

Market Signals
Indicator
GRNQ
VRAX
Relative Strength Index (RSI) 46.91 44.23
Support Level $1.51 $2.54
Resistance Level $14.40 $3.10
Average True Range (ATR) 2.65 0.17
MACD -0.79 -0.02
Stochastic Oscillator 4.34 14.29

Price Performance

Historical Comparison
GRNQ
VRAX

About GRNQ Greenpro Capital Corp.

Greenpro Capital Corp operates and provides business solution services to small and medium-sized businesses located in Southeast Asia and East Asia, with a focus on Hong Kong, China, and Malaysia, and in Thailand and Taiwan. Its range of services includes cross-border business solutions, record management services, and accounting outsourcing services. Cross-border business services include other services, tax planning, trust, & wealth management. Its segments include the Service business engaged in the provision of corporate advisory & business solution services; the Real estate business segment engaged in trading or leasing of commercial real estate properties in Hong Kong & Malaysia; & the Digital business segment engaged in the provision of digital platform & trading of digital assets.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: